Viral Conjunctivitis (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis – Drugs In Development, 2021, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 7 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Adenovir Pharma AB

EyeGate Pharmaceuticals Inc

Invirsa Inc

IVIEW Therapeutics Inc

Microbiotix Inc

NanoViricides Inc

Okogen Inc

Starpharma Holdings Ltd

TGV-Inhalonix Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Viral Conjunctivitis - Overview

Viral Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Viral Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Viral Conjunctivitis - Companies Involved in Therapeutics Development

Adenovir Pharma AB

EyeGate Pharmaceuticals Inc

Invirsa Inc

IVIEW Therapeutics Inc

Microbiotix Inc

NanoViricides Inc

Okogen Inc

Starpharma Holdings Ltd

TGV-Inhalonix Inc

Viral Conjunctivitis - Drug Profiles

APD-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EKCCide-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filociclovir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OKG-0502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

povidone iodine ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Viral Conjunctivitis - Dormant Projects

Viral Conjunctivitis - Discontinued Products

Viral Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Dec 20, 2019: iView announces first patient treated in phase 2 clinical trial program evaluating IVIEW-1201 in patients with acute adenoviral conjunctivitis

Dec 27, 2018: US FDA requests further data for VivaGel BV approval

Dec 12, 2018: US patent granted for SPL7013 eye drops for conjunctivitis

Mar 06, 2017: iVIEW Therapeutics will present its novel sustained-release povidone iodine ophthalmic formulation for the treatment of acute conjunctivitis in TechConnect World Innovation Summit & Expo and US National Innovation Summit and National SBIR/STTR Conference

Sep 12, 2016: iVIEW Therapeutics was awarded SBIR Innovative grant by NIH’s National Eye Institute

May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment

Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis

Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Viral Conjunctivitis, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Viral Conjunctivitis – Pipeline by Adenovir Pharma AB, 2021

Viral Conjunctivitis – Pipeline by EyeGate Pharmaceuticals Inc, 2021

Viral Conjunctivitis – Pipeline by Invirsa Inc, 2021

Viral Conjunctivitis – Pipeline by IVIEW Therapeutics Inc, 2021

Viral Conjunctivitis – Pipeline by Microbiotix Inc, 2021

Viral Conjunctivitis – Pipeline by NanoViricides Inc, 2021

Viral Conjunctivitis – Pipeline by Okogen Inc, 2021

Viral Conjunctivitis – Pipeline by Starpharma Holdings Ltd, 2021

Viral Conjunctivitis – Pipeline by TGV-Inhalonix Inc, 2021

Viral Conjunctivitis – Dormant Projects, 2021

Viral Conjunctivitis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Viral Conjunctivitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports